Definition
Amenable mortality is the rate of deaths from conditions considered readily treatable or preventable with timely, effective medical care — including certain infections, diabetes, appendicitis, hypertension, and selected cancers. It is used as a comparative indicator of health care system effectiveness across countries, abstracting from differences in health behaviors, socioeconomic conditions, and disease prevalence to isolate the system's capacity to treat existing illness. The standard cross-national taxonomy was codified by Nolte and McKee (2008) and updated by Gay et al. (2011) across 31 Organisation for Economic Co-operation and Development (OECD) countries.
Key Ideas
- The US amenable mortality rate fell 5% from 1998 to 2003, compared to reductions of 10–25% in other high-income countries over the same period. The US ranked last of 19 high-income countries in 2003 and fell further behind by 2008 (Nolte and McKee 2008; Gay et al. 2011).
- Amenable mortality provides a partial answer to the question of whether higher US health spending buys proportionate health improvements. The evidence suggests it does not: the US spent substantially more per capita than peer OECD countries while achieving inferior reductions in amenable mortality.
- The measure is distinct from overall or all-cause mortality — it deliberately isolates deaths that medical care can plausibly prevent or treat, making it a more direct indicator of system performance than life expectancy or total death rates.
Why It Matters
- Used to benchmark the value of US health spending relative to peer countries; reinforces the finding that 1999–2009 cost growth did not purchase commensurate health gains (Auerbach and Kellermann 2011). See Health Care Cost Growth.
- Used in policy debates about the Affordable Care Act (ACA) and system reform to argue for reorienting spending toward primary care and preventive services, where amenable mortality is most sensitive to intervention.
Open Questions
- Which specific conditions and age ranges define "amenable"? The taxonomy has evolved across studies (Nolte-McKee, Gay et al.), creating comparability issues over time and across datasets.
- To what extent does the US amenable mortality gap reflect care quality for the insured vs. access barriers for the uninsured? High US uninsurance rates could explain the gap without indicting quality for covered patients.
- Does the amenable mortality concept remain valid as disease management shifts from acute treatment to chronic condition management (e.g., cardiovascular disease prevention)?
Related
Sources